Ipsen intends to play in the big leagues.
To achieve this, the third French laboratory - behind Sanofi and Servier - is betting in particular on acquisitions.
It will thus pay nearly 1 billion euros to get its hands on the American biotech Albireo, based in Boston.
The operation, which is done with a premium of more than 100% compared to the average price of the title, allows it to strengthen itself in rare diseases, one of the three pillars of the French group with oncology and neurosciences.
"
We are convinced that this is a solid growth opportunity for Ipsen
", declared David Loew, its managing director.
Ipsen, which achieved 2.9 billion euros in sales in 2021, particularly coveted Bylvay, a "
very promising drug with potential in rare liver diseases
".
It is the first approved treatment for progressive familial intrahepatic cholestasis, a rare disease affecting bile secretion, which affects 1,250 patients…
This article is for subscribers only.
You have 75% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login